J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website https://www.jocmr.org

Original Article

Volume 13, Number 1, January 2021, pages 9-19

Percentage of Hormone Receptor Positivity in Breast Cancer Provides Prognostic Value: A Single-Institute Study

Figure 1. Patient outcomes in breast cancer patients stratified by stage. Kaplan-Meier curves of locoregional (a) and distant failure (b) as well as survival (c) in early stage breast cancer patients stratified by stage.

Figure 2. Patient outcomes in early stage breast cancer patients stratified by ER positivity. Kaplan-Meier curves of locoregional (a) and distant (b) failure as well as survival (c) in breast cancer patients stratified by percentage of ER positivity. ER: estrogen receptor.

Figure 3. Patient outcomes in early stage breast cancer patients stratified by PR percent positivity. Kaplan-Meier curves of locoregional (a) and distant (b) failure as well as survival (c) in breast cancer patients stratified by percentage of PR positivity. PR: progesterone receptor.

**Table 1.** Demographics and Tumor Characteristics of Breast Cancer Patients
	Entire cohort (n = 411)
Age, median (range)	58.0 (19.8 - 88.1)
Sex
Female	411 (100%)
BMI, median (interquartile range)	28.7 (25.2 - 34.1)
Smoking status, # at diagnosis (%)	49 (15.0%)
Year of diagnosis (median)	2014
Follow-up (months), median (mean)/(range)	36.6 (44.1)/(4.7 - 304.9)
Histology
Invasive ductal carcinoma	350
Invasive lobular carcinoma	48
Inflammatory	2
Metaplastic carcinoma	2
Mixed	7
Unknown	2
Grade
I	83
II	154
III	168
Unknown	6
T stage
T0	2
T1a	32
T1b	65
T1c	127
T2	132
T3	41
T4	1
T4b	3
T4c	1
T4d	5
Unknown	2
Overall stage
I	184
II	159
III	68

Table 1. Demographics and Tumor Characteristics of Breast Cancer Patients

Entire cohort (n = 411)

Age, median (range)

58.0 (19.8 - 88.1)

Sex

Female

411 (100%)

BMI, median (interquartile range)

28.7 (25.2 - 34.1)

Smoking status, # at diagnosis (%)

49 (15.0%)

Year of diagnosis (median)

2014

Follow-up (months), median (mean)/(range)

36.6 (44.1)/(4.7 - 304.9)

Histology

Invasive ductal carcinoma

350

Invasive lobular carcinoma

Inflammatory

Metaplastic carcinoma

Mixed

Unknown

Grade

154

III

168

Unknown

T stage

T1a

T1b

T1c

127

132

T4b

T4c

T4d

Unknown

Overall stage

184

159

III

**Table 2.** Cox PH Univariate and Multivariate Analysis for Percentage of ER Positivity, Percentage of PR Positivity, and Stage for Local Failure
Parameter	Univariate	Multivariate
This evaluation was performed considering ER and PR positivity as both ^acategorical (top) and ^bcontinuous variables (bottom). ER: estrogen receptor; PR: progesterone receptor.
ER group^a
0%	Reference
1-79%	0.24	0.04	0.88	0.063	0.09	0.01	0.46	0.009
> 80%	0.20	0.07	0.55	0.003	0.09	0.02	0.37	< 0.001
PR group^a
0%	Reference
1-79%	0.69	0.23	2.02	0.507	3.96	0.90	15.17	0.060
> 80%	0.53	0.15	1.69	0.317	3.10	0.61	14.16	0.168
Stage^a
1	Reference
2 vs. 1	0.57	0.16	1.82	0.375	0.61	0.16	2.00	0.443
3 vs. 1	1.76	0.57	5.29	0.333	1.65	0.53	4.93	0.390
ER% increase^b	0.98	0.97	0.99	0.004	0.98	0.96	0.99	0.007
PR% increase^b	0.99	0.98	1.00	0.225	1.01	0.99	1.02	0.387
Stage^b 2 vs. 1	0.57	0.16	1.82	0.375	0.55	0.15	1.78	0.872
Stage^b 3 vs. 1	1.76	0.57	5.29	0.333	1.57	0.52	4.64	0.613

Table 2. Cox PH Univariate and Multivariate Analysis for Percentage of ER Positivity, Percentage of PR Positivity, and Stage for Local Failure

Parameter

Univariate

Multivariate

Hazard ratio

95% hazard ratio, confidence limits

Pr > ChiSq

Hazard ratio

95% hazard ratio, confidence limits

Pr > ChiSq

This evaluation was performed considering ER and PR positivity as both ^acategorical (top) and ^bcontinuous variables (bottom). ER: estrogen receptor; PR: progesterone receptor.

ER group^a

Reference

1-79%

0.24

0.04

0.88

0.063

0.09

0.01

0.46

0.009

> 80%

0.20

0.07

0.55

0.003

0.09

0.02

0.37

< 0.001

PR group^a

Reference

1-79%

0.69

0.23

2.02

0.507

3.96

0.90

15.17

0.060

> 80%

0.53

0.15

1.69

0.317

3.10

0.61

14.16

0.168

Stage^a

Reference

2 vs. 1

0.57

0.16

1.82

0.375

0.61

0.16

2.00

0.443

3 vs. 1

1.76

0.57

5.29

0.333

1.65

0.53

4.93

0.390

ER% increase^b

0.98

0.97

0.99

0.004

0.98

0.96

0.99

0.007

PR% increase^b

0.99

0.98

1.00

0.225

1.01

0.99

1.02

0.387

Stage^b 2 vs. 1

0.57

0.16

1.82

0.375

0.55

0.15

1.78

0.872

Stage^b 3 vs. 1

1.76

0.57

5.29

0.333

1.57

0.52

4.64

0.613

**Table 3.** Cox PH Univariate and Multivariate Analysis for Percentage of ER Positivity, Percentage of PR Positivity, and Stage for Distant Failure
Parameter	Univariate	Multivariate
This evaluation was performed considering ER and PR positivity as both ^acategorical (top) and ^bcontinuous variables (bottom). ER: estrogen receptor; PR: progesterone receptor.
ER group^a
0%	Reference
1-79%	1.14	0.38	3.23	0.813	1.01	0.27	3.34	0.988
> 80%	0.56	0.24	1.37	0.194	0.97	0.27	3.31	0.960
PR group^a
0%	Reference
1-79%	1.02	0.45	2.31	0.973	1.01	0.35	3.32	0.987
> 80%	0.33	0.10	0.92	0.051	0.36	0.08	1.48	0.161
Stage^a
1	Reference
2 vs. 1	4.23	1.44	16.40	0.020	4.22	1.44	16.34	0.020
3 vs. 1	7.85	2.57	30.00	0.001	7.00	2.27	27.90	0.002
ER% increase^b	0.99	0.98	1.00	0.090	1.00	0.99	1.01	0.951
PR% increase^b	0.99	0.98	0.99	0.030	0.99	0.98	1.00	0.119
Stage^b 2 vs. 1	4.23	1.44	16.40	0.020	4.24	1.44	16.45	0.019
Stage^b 3 vs. 1	7.85	2.57	30.99	0.001	7.00	2.29	27.72	0.002

Table 3. Cox PH Univariate and Multivariate Analysis for Percentage of ER Positivity, Percentage of PR Positivity, and Stage for Distant Failure

Parameter

Univariate

Multivariate

Hazard ratio

95% hazard ratio, confidence limits

Pr > ChiSq

Hazard ratio

95% hazard ratio, confidence limits

Pr > ChiSq

This evaluation was performed considering ER and PR positivity as both ^acategorical (top) and ^bcontinuous variables (bottom). ER: estrogen receptor; PR: progesterone receptor.

ER group^a

Reference

1-79%

1.14

0.38

3.23

0.813

1.01

0.27

3.34

0.988

> 80%

0.56

0.24

1.37

0.194

0.97

0.27

3.31

0.960

PR group^a

Reference

1-79%

1.02

0.45

2.31

0.973

1.01

0.35

3.32

0.987

> 80%

0.33

0.10

0.92

0.051

0.36

0.08

1.48

0.161

Stage^a

Reference

2 vs. 1

4.23

1.44

16.40

0.020

4.22

1.44

16.34

0.020

3 vs. 1

7.85

2.57

30.00

0.001

7.00

2.27

27.90

0.002

ER% increase^b

0.99

0.98

1.00

0.090

1.00

0.99

1.01

0.951

PR% increase^b

0.99

0.98

0.99

0.030

0.99

0.98

1.00

0.119

Stage^b 2 vs. 1

4.23

1.44

16.40

0.020

4.24

1.44

16.45

0.019

Stage^b 3 vs. 1

7.85

2.57

30.99

0.001

7.00

2.29

27.72

0.002

**Table 4.** Cox PH Univariate and Multivariate Analysis for Percentage of ER Positivity, Percentage of PR Positivity, and Stage for Survival
Parameter	Univariate	Multivariate
This evaluation was performed considering ER and PR positivity as both ^acategorical (top) and ^bcontinuous variables (bottom). ER: estrogen receptor; PR: progesterone receptor.
ER group^a
0%	Reference
1-79%	0.30	0.06	1.07	0.107	0.08	0.01	0.48	0.008
> 80%	0.20	0.07	0.56	0.004	0.10	0.03	0.51	0.003
PR group^a
0%	Reference
1-79%	0.73	0.26	2.00	0.556	4.60	0.92	18.33	0.046
> 80%	0.25	0.05	0.90	0.064	1.13	0.17	5.45	0.890
Stage^a
1	Reference
2 vs. 1	5.28	1.18	49.76	0.072	5.60	1.23	53.12	0.065
3 vs. 1	11.59	2.58	109.54	0.009	11.77	2.59	111.77	0.008
ER% increase^b	0.98	0.97	0.99	0.003	0.99	0.97	1.00	0.119
PR% increase^b	0.98	0.97	0.99	0.014	0.99	0.97	1.01	0.336
Stage^b 2 vs. 1	5.28	1.18	49.76	0.073	4.97	1.11	46.88	0.085
Stage^b 3 vs. 1	11.59	2.58	109.54	0.008	10.22	2.29	96.30	0.012

Table 4. Cox PH Univariate and Multivariate Analysis for Percentage of ER Positivity, Percentage of PR Positivity, and Stage for Survival

Parameter

Univariate

Multivariate

Hazard ratio

95% hazard ratio, confidence limits

Pr > ChiSq

Hazard ratio

95% hazard ratio, confidence limits

Pr > ChiSq

This evaluation was performed considering ER and PR positivity as both ^acategorical (top) and ^bcontinuous variables (bottom). ER: estrogen receptor; PR: progesterone receptor.

ER group^a

Reference

1-79%

0.30

0.06

1.07

0.107

0.08

0.01

0.48

0.008

> 80%

0.20

0.07

0.56

0.004

0.10

0.03

0.51

0.003

PR group^a

Reference

1-79%

0.73

0.26

2.00

0.556

4.60

0.92

18.33

0.046

> 80%

0.25

0.05

0.90

0.064

1.13

0.17

5.45

0.890

Stage^a

Reference

2 vs. 1

5.28

1.18

49.76

0.072

5.60

1.23

53.12

0.065

3 vs. 1

11.59

2.58

109.54

0.009

11.77

2.59

111.77

0.008

ER% increase^b

0.98

0.97

0.99

0.003

0.99

0.97

1.00

0.119

PR% increase^b

0.98

0.97

0.99

0.014

0.99

0.97

1.01

0.336

Stage^b 2 vs. 1

5.28

1.18

49.76

0.073

4.97

1.11

46.88

0.085

Stage^b 3 vs. 1

11.59

2.58

109.54

0.008

10.22

2.29

96.30

0.012